抗CD38联合抗CD20挽救治疗移植后复发性FSGS
这项法国12中心回顾性研究纳入17例肾移植后复发性FSGS患者,在抗CD20基础上加用达雷妥尤单抗(抗CD38)。首疗程后41%达完全缓解、24%部分缓解,中位应答时间24天,尿蛋白从3.9 g/g降至1.4 g/g(P=0.029),耐受良好。
要点
- 复发性FSGS移植后患者联合清除浆细胞与B细胞可获41%完全缓解、24%部分缓解。
- 中位应答时间24天,所有应答者均成功停用血浆置换。
- 中位随访8个月,3例应答者复发但再治疗后重获缓解。
核心结论
- 在难治性复发性FSGS中,联合浆细胞与B细胞清除与有意义的缓解率相关。
- 部分病例抗nephrin抗体呈与临床应答平行的动态变化。
研究设计与样本
- 法国12中心回顾性研究,纳入17例接受达雷妥尤单抗(抗CD38)治疗的肾移植后复发性FSGS受者。
- 达雷妥尤单抗在抗CD20治疗后和/或与抗CD20联合使用,治疗起始时进行临床与组织学特征描述。
主要发现
- 从复发到达雷妥尤单抗启动的中位时间为5个月,所有患者既往均接受过B细胞清除治疗。
- 首疗程达雷妥尤单抗(1-8次注射)后,7例(41%)达完全缓解,4例(24%)达部分缓解,所有应答者均停用血浆置换。
- 中位应答时间24天;中位随访8个月期间,3例应答者复发但再治疗后重获缓解。
- 中位尿蛋白从3.9 g/g降至1个月时1.4 g/g(P = 0.029)。
- 11例受检者中3例抗nephrin抗体阳性,其中2例治疗后显著下降并与临床应答平行,1例未下降;治疗耐受良好。
临床怎么用
- 对标准治疗抵抗的移植后复发性FSGS,可考虑在抗CD20基础上联合抗CD38清除浆细胞。
- 治疗应答可较快出现(中位24天),应答者有望停用血浆置换。
局限性
- 回顾性设计、样本量小(17例),缺乏对照。
- 抗nephrin抗体仅在11例中检测,数据有限。
- 随访时间较短(中位8个月),最佳患者选择与剂量尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recurrent focal segmental glomerulosclerosis (FSGS, rFSGS) is a severe complication after kidney transplantation, often resistant to standard therapies and requiring prolonged apheresis. Combined depletion of plasma cells (anti-CD38) and B cells (anti-CD20) has emerged as a potential strategy; however, multicenter real-world data integrating clinical, biological, and histological characterization remain limited. METHODS: We retrospectively studied 17 kidney transplant recipients with rFSGS treated with daratumumab (anti-CD38) administered after and/or in combination with anti-CD20 therapy across 12 French centers. Patients were clinically and histologically characterized at treatment initiation. Clinical response, safety, and longitudinal antinephrin antibody trajectories were assessed. RESULTS: Median time from recurrence to daratumumab initiation was 5 months. All patients had previously received B-cell-depleting therapy. After the first daratumumab course (1-8 injections), 7 patients (41%) achieved complete remission (CR) and 4 (24%) achieved partial remission (PR), allowing discontinuation of apheresis in all responders. Median response time was 24 days. During a median follow-up of 8 months, 3 responders relapsed but regained remission after retreatment. Median proteinuria decreased from 3.9 g/g to 1.4 g/g at 1 month (P = 0.029). Among 11 patients tested, 3 had positive antinephrin antibodies. Two patients showed marked posttreatment declines paralleling clinical response, whereas 1 did not. Treatment was well-tolerated. CONCLUSION: In this multicenter real-world cohort, combined plasma cell and B-cell depletion was associated with meaningful remission rates in refractory rFSGS and was accompanied by dynamic changes in antinephrin antibodies in selected cases. Prospective trials are warranted to define optimal patient selection and dosing, and to clarify its place in therapy.
引用
- Leon J, Ducrocq E, Lafargue MC, et al. Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS. Kidney Int Rep. 2026. PMID: 42571438. doi:10.1016/j.ekir.2026.106668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。